Ascendis Pharma A/S $ASND Stock Position Decreased by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD reduced its stake in Ascendis Pharma A/S by 1.2%, owning 2,256,102 shares valued at approximately $351.6 million as of its latest SEC filing.
• Ascendis Pharma's recent earnings report showed an EPS of ($0.93), surpassing analyst expectations of ($1.42) and generating $216.28 million in revenue against projected $163.17 million.
• Equities research analysts maintain a strong outlook for Ascendis Pharma, with the stock receiving a majority of Buy ratings and an average price target of $243.36.

Price T Rowe Associates Inc. MD trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,256,102 shares of the biotechnology company's stock after selling 27,105 shares during the quarter. Price T Rowe Associates Inc. MD owned about 3.70% of Ascendis Pharma A/S worth $351,637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. RA Capital Management L.P. raised its position in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the period. Janus Henderson Group PLC increased its position in Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after acquiring an additional 193,688 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Ascendis Pharma A/S by 12.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after acquiring an additional 328,278 shares during the period. Massachusetts Financial Services Co. MA increased its position in Ascendis Pharma A/S by 0.6% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,877,917 shares of the biotechnology company's stock valued at $292,692,000 after acquiring an additional 10,366 shares during the period. Finally, Invesco Ltd. increased its position in Ascendis Pharma A/S by 3.7% in the 1st quarter. Invesco Ltd. now owns 1,198,478 shares of the biotechnology company's stock valued at $186,795,000 after acquiring an additional 42,465 shares during the period.

Analysts Set New Price Targets

Several analysts recently commented on ASND shares. Morgan Stanley started coverage on Ascendis Pharma A/S in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 target price on the stock. Cantor Fitzgerald raised their target price on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. UBS Group restated a "buy" rating and issued a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Oppenheimer reiterated an "outperform" rating and set a $224.00 price target (up from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Finally, Cowen reiterated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of "Buy" and a consensus price target of $243.36.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $1.49 during trading hours on Friday, hitting $192.41. 70,353 shares of the company were exchanged, compared to its average volume of 489,626. The company has a market capitalization of $11.78 billion, a PE ratio of -37.41 and a beta of 0.41. The firm has a fifty day simple moving average of $179.84 and a 200-day simple moving average of $165.40. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.